JP2013529894A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013529894A5 JP2013529894A5 JP2013503962A JP2013503962A JP2013529894A5 JP 2013529894 A5 JP2013529894 A5 JP 2013529894A5 JP 2013503962 A JP2013503962 A JP 2013503962A JP 2013503962 A JP2013503962 A JP 2013503962A JP 2013529894 A5 JP2013529894 A5 JP 2013529894A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- vlp
- control element
- recombinant nucleic
- parvovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32185610P | 2010-04-07 | 2010-04-07 | |
| US61/321,856 | 2010-04-07 | ||
| PCT/US2011/031630 WO2011127316A1 (en) | 2010-04-07 | 2011-04-07 | Method for generating a parvovirus b19 virus-like particle |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016000272A Division JP2016041085A (ja) | 2010-04-07 | 2016-01-04 | パルボウイルスｂ１９のウイルス様粒子を生成するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013529894A JP2013529894A (ja) | 2013-07-25 |
| JP2013529894A5 true JP2013529894A5 (https=) | 2014-03-06 |
Family
ID=44170068
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013503962A Pending JP2013529894A (ja) | 2010-04-07 | 2011-04-07 | パルボウイルスｂ１９のウイルス様粒子を生成するための方法 |
| JP2016000272A Pending JP2016041085A (ja) | 2010-04-07 | 2016-01-04 | パルボウイルスｂ１９のウイルス様粒子を生成するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016000272A Pending JP2016041085A (ja) | 2010-04-07 | 2016-01-04 | パルボウイルスｂ１９のウイルス様粒子を生成するための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9744228B2 (https=) |
| EP (1) | EP2556151A1 (https=) |
| JP (2) | JP2013529894A (https=) |
| BR (1) | BR112012025364A2 (https=) |
| WO (1) | WO2011127316A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2646669T3 (es) | 2010-07-06 | 2017-12-14 | Glaxosmithkline Biologicals Sa | Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN |
| ES2557382T3 (es) | 2010-07-06 | 2016-01-25 | Glaxosmithkline Biologicals Sa | Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN |
| EP2591114B1 (en) | 2010-07-06 | 2016-06-08 | GlaxoSmithKline Biologicals SA | Immunisation of large mammals with low doses of rna |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| LT4226941T (lt) | 2010-08-31 | 2025-01-10 | Glaxosmithkline Biologicals Sa | Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2012051211A2 (en) | 2010-10-11 | 2012-04-19 | Novartis Ag | Antigen delivery platforms |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| EP2729165B1 (en) * | 2011-07-06 | 2017-11-08 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| CA2841047A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| WO2014028429A2 (en) | 2012-08-14 | 2014-02-20 | Moderna Therapeutics, Inc. | Enzymes and polymerases for the synthesis of rna |
| PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| EP2968391A1 (en) | 2013-03-13 | 2016-01-20 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US9632087B2 (en) * | 2013-09-10 | 2017-04-25 | MockV Solutions | Methods for evaluating viral clearance from a biopharmaceutical solution employing mock viral particles |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| HUE065661T2 (hu) | 2015-09-29 | 2024-06-28 | Boehringer Ingelheim Animal Health Usa Inc | Kutya parvovírus (CPV) vírusszerû részecske (VLP) vakcinák és alkalmazásuk |
| EP3359670B2 (en) | 2015-10-05 | 2024-02-14 | ModernaTX, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
| CN108794583B (zh) * | 2018-05-31 | 2021-11-02 | 中国农业科学院特产研究所 | 貉细小病毒病毒样颗粒、其制备方法与应用以及该病毒样颗粒制备的疫苗 |
| WO2020067027A1 (ja) * | 2018-09-28 | 2020-04-02 | 一般財団法人阪大微生物病研究会 | Ｖｌｐ発現ｃｈｏ細胞株の構築 |
| US11191824B1 (en) * | 2020-05-22 | 2021-12-07 | The Government of the United States of America, as represented by the Secretary of Homeland Security | Method of purifying virus-like-particles |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
| US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| AU631377B2 (en) | 1988-08-25 | 1992-11-26 | Liposome Company, Inc., The | Affinity associated vaccine |
| JP2755817B2 (ja) | 1988-11-14 | 1998-05-25 | アメリカ合衆国 | パルボウイルスキャプシド |
| US6379885B1 (en) * | 1989-09-14 | 2002-04-30 | Rijksuniversiteit Te Leiden | Human parvovirus B19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines |
| US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| US5340740A (en) | 1992-05-15 | 1994-08-23 | North Carolina State University | Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process |
| CA2138997C (en) | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| JPH07147986A (ja) * | 1992-09-24 | 1995-06-13 | Denki Kagaku Kogyo Kk | ヒトパルボウイルス遺伝子、それによってコ−ドされるポリペプチド及び用途 |
| US5776468A (en) | 1993-03-23 | 1998-07-07 | Smithkline Beecham Biologicals (S.A.) | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A |
| GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| FR2726003B1 (fr) | 1994-10-21 | 2002-10-18 | Agronomique Inst Nat Rech | Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| DK1005368T3 (da) | 1997-03-10 | 2010-01-04 | Ottawa Hospital Res Inst | Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer |
| US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
| US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| US6348450B1 (en) | 1997-08-13 | 2002-02-19 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom and uses thereof |
| AU1145699A (en) | 1997-09-05 | 1999-03-22 | Smithkline Beecham Biologicals (Sa) | Oil in water emulsions containing saponins |
| GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| CA2312900A1 (en) | 1997-12-02 | 1999-06-10 | Powderject Vaccines, Inc. | Transdermal delivery of particulate vaccine compositions |
| IL137809A0 (en) | 1998-02-12 | 2001-10-31 | American Cyanamid Co | Pneumococcal and meningococcal vaccines formulated with interleukin-12 |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| WO1999052549A1 (en) | 1998-04-09 | 1999-10-21 | Smithkline Beecham Biologicals S.A. | Adjuvant compositions |
| US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| US6743772B1 (en) * | 1998-11-24 | 2004-06-01 | Kristina Broliden | Use of parovirus capsid particles in the inhibition of cell proliferation and migration |
| TR200200777T2 (tr) | 1999-09-24 | 2002-09-23 | Smithkline Beecham Biologicals S.A. | Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant. |
| US20010044416A1 (en) | 2000-01-20 | 2001-11-22 | Mccluskie Michael J. | Immunostimulatory nucleic acids for inducing a Th2 immune response |
| SI1354204T2 (sl) | 2000-06-15 | 2010-09-30 | Novartis Vaccines & Diagnostic | Hcv antigen antitelo kombinacijska analiza |
| AU2001294750C1 (en) | 2000-09-26 | 2008-09-18 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| DK1372708T3 (da) | 2001-02-13 | 2008-10-20 | Us Gov Sec Army | Vaccine til transkutan immunisering mod rejsediarre |
| JP2004529906A (ja) | 2001-03-19 | 2004-09-30 | イオマイ コーポレイシヨン | 経皮的免疫賦活 |
| ES2537549T3 (es) * | 2001-06-28 | 2015-06-09 | Grifols Worldwide Operations Limited | Ensayos de diagnóstico para parvovirus B19 |
| GB0123580D0 (en) | 2001-10-01 | 2001-11-21 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| FR2832423B1 (fr) | 2001-11-22 | 2004-10-08 | Vivalis | Systeme d'expression de proteines exogenes dans un systeme aviaire |
| FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| EP2149583B1 (en) | 2004-09-24 | 2015-10-28 | Novartis AG | Modified VP1-capsid protein of parvovirus B19 |
| US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
| ES2514316T3 (es) | 2005-11-22 | 2014-10-28 | Novartis Vaccines And Diagnostics, Inc. | Partículas similares a virus (VLPs) de Norovirus y Sapovirus |
| WO2007084773A2 (en) * | 2006-01-20 | 2007-07-26 | University Of North Carolina At Chapel Hill | Enhanced production of infectious parvovirus vectors in insect cells |
| US20080044438A1 (en) * | 2006-03-17 | 2008-02-21 | Ostroff Gary R | Yeast Cell Particles As Oral Delivery Vehicles For Antigens |
| US20110165626A1 (en) * | 2006-10-03 | 2011-07-07 | Centre National De La Recherche Scientifique (Cnrs | High yield production of sialic acid (neu5ac) by fermentation |
-
2011
- 2011-04-07 US US13/639,820 patent/US9744228B2/en not_active Expired - Fee Related
- 2011-04-07 BR BR112012025364A patent/BR112012025364A2/pt not_active IP Right Cessation
- 2011-04-07 WO PCT/US2011/031630 patent/WO2011127316A1/en not_active Ceased
- 2011-04-07 EP EP11716449A patent/EP2556151A1/en not_active Ceased
- 2011-04-07 JP JP2013503962A patent/JP2013529894A/ja active Pending
-
2016
- 2016-01-04 JP JP2016000272A patent/JP2016041085A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013529894A5 (https=) | ||
| US12065467B2 (en) | High-transduction-efficiency rAAV vectors, compositions, and methods of use | |
| CN112480217B (zh) | 基于SARS-CoV-2的S抗原蛋白的疫苗和组合物 | |
| US20180105559A1 (en) | Aav vectors with high transduction efficiency and uses thereof for gene therapy | |
| US9611302B2 (en) | High-transduction-efficiency RAAV vectors, compositions, and methods of use | |
| JP2024525709A (ja) | 脂質ナノエマルション粒子に吸着したｒｎａとその製剤 | |
| KR20220127851A (ko) | 핵산 로딩된 적혈구 세포외 소포 | |
| JP2025098089A (ja) | ＨＰＶ ｍＲＮＡを封入した核酸脂質粒子ワクチン | |
| Zheng et al. | Respiratory syncytial virus F subunit vaccine with AS02 adjuvant elicits balanced, robust humoral and cellular immunity in BALB/c mice | |
| KR20230116801A (ko) | 고초균에 있어서의 바이러스 벡터 플라스미드 생산 | |
| US20250195693A1 (en) | Compositions Comprising Adeno-Associated Virus Chimera Capsid Proteins and Methods of Using the Same | |
| JP2023536160A (ja) | 改変チクングニアウイルス及びシンドビスウイルス並びにそれらの用途 | |
| CN118806887A (zh) | 一种基于纳米脂质体的猴痘病毒mRNA疫苗及其应用 | |
| WO2022244815A1 (ja) | Ｈｐｖ感染症ワクチン | |
| US20240417698A1 (en) | A method for production of self-replicating, nucleic acid-loaded, virus-like particles (vlp-na) and the uses thereof | |
| Fassnacht et al. | Immunization with dendritic cells can break immunological ignorance toward a persisting virus in the central nervous system and induce partial protection against intracerebral viral challenge | |
| Fath-Bayati et al. | Tracking of intraperitoneally and direct intrahepatic administered mesenchymal stem cells expressing miR-146a-5p in mice hepatic tissue | |
| KR20250123985A (ko) | 노로바이러스 GII mRNA를 포함하는 백신 조성물 | |
| KR20240104032A (ko) | 이중나선 dna가 결합된 금 나노 입자 운반체를 포함하는 백신 조성물 | |
| KR20250093673A (ko) | PE (Purification Enhancer)와 PEC (Purification Enhancer Complement)를 적용한 원형 RNA 제조방법 | |
| CN119301261A (zh) | 经修饰的西方马脑炎病毒及其用途 | |
| HK40074627A (en) | Nucleic acid lipid particle vaccine encapsulating hpv mrna | |
| HK40047436A (zh) | 基於sars-cov-2的s抗原蛋白的疫苗和组合物 | |
| HK40047436B (en) | Vaccines and compositions based on s antigen protein of sars-cov-2 | |
| EA051673B1 (ru) | Рнк, адсорбированная на частицах наноэмульсии липидов, и ее композиции |